The Partnership Fund has participated in the $48 million Series A investment of Petra Pharma Corporation to develop small molecule inhibitors for the treatment of cancer and metabolic diseases. The investment signifies a step forward in strengthening the biotech sector in New York, which has yet to capitalize on its wealth of the academic institutions, but is seeing an influx of new early stage venture investors like Accelerator Corp.